Iterum Therapeutics plc
Fitzwilliam Court
1st Floor Leeson Close
Dublin D02 YW24
Ireland
353 1 669 4820
https://www.iterumtx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 14
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Corey N. Fishman | President, CEO & Director | 1.3M | 無 | 1965 |
| Ms. Judith M. Matthews | Chief Financial Officer | 747.77k | 無 | 1970 |
| Dr. Michael W. Dunne M.D. | Strategic Advisor & Director | 115k | 無 | 1960 |
| Dr. Sailaja Puttagunta M.D. | Chief Medical Officer | 946.83k | 無 | 1969 |
| Mr. Tom Loughman Ph.D. | Senior Vice President of Technical Operations | 無 | 無 | 無 |
| Ms. Louise Barrett | Senior Vice President of Legal Affairs & Secretary | 無 | 無 | 無 |
| Dr. Steven I. Aronin M.D. | Senior VP & Head of Clinical Development | 無 | 無 | 無 |
截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。
描述
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
公司管治
截至 無 止，Iterum Therapeutics plc 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。
企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。
